HIV AND HEPATITIS B CURE: Edited by Sharon R. Lewin and Peter A. RevillIn-vitro and in-vivo models for hepatitis B cure researchAllweiss, Lenaa; Strick-Marchand, Heleneb,cAuthor Information aDepartment of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany bInnate Immunity Unit, Institut Pasteur cInserm U1223, Paris, France Correspondence to Helene Strick-Marchand, Innate Immunity Unit, Institut Pasteur, 75724 Paris, France. Tel: +33 1 4061 3209; e-mail: firstname.lastname@example.org Current Opinion in HIV and AIDS: May 2020 - Volume 15 - Issue 3 - p 173-179 doi: 10.1097/COH.0000000000000616 Buy Metrics Abstract Purpose of review Antiviral therapy for chronic hepatitis B infection is rarely curative, thus research in HBV cure strategies is a priority. Drug development and testing has been hampered by the lack of robust cell culture systems and small animal models. This review summarizes existing models for HBV cure research and focuses on recent developments since 2017 until today. Recent findings The field has progressed in the development of cell culture and animal models to study HBV. Although early cell culture systems relied on transfection of HBV genomes in hepatoma cell lines, novel models expressing the entry receptor for HBV are susceptible to infection. Improved culture conditions for primary human hepatocytes, the primary target of HBV, have enabled the screening and validation of novel antivirals. Mouse models grafted with partially humanized livers are suitable for testing viral entry inhibitors or direct acting antivirals, and can be reconstituted with human immune cells to analyze immunotherapies. Other immunocompetent models include mice transduced with HBV genomes or woodchucks infected with their native hepatitis virus. Summary Model systems for HBV research have helped lay the groundwork for the development and optimization of antiviral and immune-based therapeutic approaches that are now moving to clinical trials. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.